Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II preoperative GA vs GS for resectable pancreatic ductal adenocarcinoma
jRCTs051180122Phase 2Completed
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine + S-1 (GS) arm with Gemcitabine + nab-paclitaxel (GA) arm (2 arms). Primary endpoint: Progression-free survival time. Started Apr 2016; status: completed.
02
Drugs
gemcitabinetegafurpaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs051180122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180122.